On July 21, 2026, Greenland Mines Ltd. declared a dividend of one right for each outstanding share of Common Stock, payable on August 7, 2026, to stockholders of record as of that date. This establishes a limited-duration stockholder rights plan (poison pill) effective July 22, 2026, expiring July 22, 2027. The rights become exercisable if a person or group acquires 15% or more of outstanding common shares, allowing holders to purchase shares at an exercise price of $0.75. The plan includes flip-in and flip-over triggers to discourage coercive takeover tactics. The company operates in the mining and biotech industries, focusing on rare earth and precious metals exploration in Greenland and ALS therapeutic development.

Greenland Mines Ltd announced the completion of a Technical Report Summary (TRS) for the Skaergaard project in southeast Greenland, marking its first S-K 1300-compliant report. An updated 2026 Mineral Resource Estimate (MRE) shows a 31% increase in Indicated PdEq contained metal (11.41 Moz to 15.00 Moz) and a 24% increase in Inferred PdEq contained metal (14.11 Moz to 17.49 Moz) compared to 2022. Indicated PdEq grade rose 36% to 3.04 g/t, and Inferred PdEq grade rose 44% to 3.07 g/t. These upgrades were driven by an improved geological block model and updated metal prices, including gold at $3,500/oz. The company intends to use this regulatory foundation to proceed toward an Initial Assessment evaluating open-pit and underground mining scenarios. The company operates in the mining and biotech industries, focusing on the exploration and development of precious and critical metals.

On July 4, 2026, Greenland Mines Ltd. terminated its At-the-Market Sales Agreement with A.G.P./Alliance Global Partners that had been in place since July 3, 2025. The company terminated the agreement as of right without incurring any penalties, and no shares remained available for sale under the agreement. The company operates in the mining industry, focusing on mineral exploration and extraction.